ZLAB Zai Lab Ltd Earnings per share for the last twelve months

Corporate company logo of Zai Lab Corp (ZLAB)

Anticipated profits from oncology drugs and Chinese government reimbursement systems have driven the price action for Zai Lab Limited (ZLAB). The current annual net income per share illustrates this trend, with the actual value standing at -1.78. Such resilience is based on the company's role as the exclusive conduit for Western technologies in Asia, which has solidified the brand's status as an authoritative and reliable partner for global biotechs.

ZLAB (Zai Lab Corp) Earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Financial and market metric breakdowns for Zai Lab Ltd (ZLAB)

- current quotes and average value forecast:
Price Chart Zai Lab Limited|ZLAB - Average Forecast Price
- market capitalization data:
Market Value Zai Lab Limited|ZLAB - Total Company Value
- shareholders' equity book value data:
Book Value per Share Zai Lab|ZLAB - Accounting Capitalization|Market Capitalization to Book Value Ratio zailaboratory.com|ZLAB - Company Total Asset Base
- company total debt and liquidity indicators:
Debt to Equity Zai Lab Limited|ZLAB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Zai Lab Ltd.|ZLAB - Company Total Indebtedness|Debt to Book Value Zai Lab Limited|ZLAB - Long-Term Liabilities|Company Short-Term Debts Zai Lab|Quick Ratio zailaboratory.com
- net income and valuation multiples indicators:
ZLAB - Net Financial Result|Future Profit Zai Lab Limited|ZLAB - Company Value to Net Income|Future Price to Earnings Zai Lab|ZLAB - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Zai Lab Limited|ZLAB - Operating profit EBITDA|Net earnings per share (EPS TTM) Zai Lab|ZLAB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zailaboratory.com|ZLAB - Earnings per share increase in current year|Net earnings per share growth forecast for next year Zai Lab Limited
Comprehensive company analysis:Zai Lab Limited - ZLAB
Mass-produced product of Zai Lab Ltd

For the conservative investor, the trailing 12-month net income per share serves as the benchmark for real capital efficiency, eliminating distortions caused by share buybacks. In the case of Zai Lab Limited (ZLAB), this indicator confirms financial stability during the expansion of a diversified drug portfolio in Asia, allowing for an assessment of the biopharmaceutical holding's ability to convert innovative licenses into a stable cash flow per share.

Key competitors

LLY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months abbvie.com|AstraZeneca (AZN) - Earnings per share for the last twelve months|NVS (Novartis Corporation) - Earnings per share for the last twelve months|MRK (Merck Sharp & Dohme) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVO (Novo Nordisk Group)|Net earnings per share (EPS TTM) AMGN|Net earnings per share for the last four quarters pfizer.com|Earnings per share for the last twelve months Sanofi S.A. SNY|BMY: Earnings per share for the last 12 months|GSK Corp - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Takeda Pharma (TAK)|TEVA (tevapharm.com) - Net earnings per share for the last 12 months|Earnings per one share for the last 12 months RDY (drreddys.com)|VTRS (Viatris) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Roivant|Net earnings per share (EPS TTM) BHC|Net earnings per share for the last four quarters Cosmos Health Inc